In a study including 44 sporadic adrenocortical tumors (29 adenomas and 15 cancers), 17q22-24 losses were noted in 23% of adenomas and 53% of cancers, with inactivating PRKAR1A mutations identified in three tumors [11]. Here, PRKAR1A is linked to cancer.